WEKO3
アイテム
Biomarkers for cardiovascular diseases: their clinical significances and future directions
https://asahikawa-med.repo.nii.ac.jp/records/5693
https://asahikawa-med.repo.nii.ac.jp/records/56930a314e6e-534b-4cf8-9e78-8cf3a30b361e
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
6754.pdf (427.6 kB)
|
|
| Item type | 学術雑誌論文 / Journal Article_02(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2017-07-19 | |||||
| タイトル | ||||||
| タイトル | Biomarkers for cardiovascular diseases: their clinical significances and future directions | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Biomarker | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | High-risk patients | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Vascular function | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| 著者 |
藤井, 聡
× 藤井, 聡× 伊藤, 敦巳× 渡辺, 愉美 |
|||||
| 著者 ローマ字 | ||||||
| 値 | Fujii, Satoshi | |||||
| 著者 ローマ字 | ||||||
| 値 | Ito, Atsushi | |||||
| 著者 ローマ字 | ||||||
| 値 | Watanabe, Yumi | |||||
| 書誌情報 |
Annals of Nuclear Cardiology 巻 2, 号 1, p. 94-98, 発行日 2016-02-01 |
|||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 2189-3926 | |||||
| DOI | ||||||
| 関連タイプ | isVersionOf | |||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | http://doi.org/10.17996/ANC.02.01.94 | |||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Biomarkers are used for evaluation of the pathophysiological state, risk stratification, diagnostic tools, staging of a disease and responsiveness to treatment. Representative biomarkers used in cardiovascular diseases may include C-reactive protein (CRP) for inflammation, brain natriuretic peptide (BNP), atrial natriuretic peptide (ANP), aldosterone, renin for neurohumoral factors, plasminogen activator inhibitor type-1 (PAI-1) for fibrinolysis and endothelial function, d-dimer for thrombosis, urine albumin/creatinine ratio for renal glomerular endothelial function. Further addition of new biomarkers may increase the capacity to find high-risk patients with cardiovascular diseases. In this review we would like to introduce several representative biomarkers in the context of nuclear cardiology. With the advancement of new imaging modalities new biomarkers are readily available. Combined use of new nuclear cardiology modalities with biomarkers one would establish prevention guidelines and classify high-risk subgroups needing treatment intervention. | |||||
| 資源タイプ | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | text | |||||
| 著者版フラグ | ||||||
| 出版タイプ | AM | |||||
| 出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
| フォーマット | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | application/pdf | |||||
| ID(XooNIps) | ||||||
| 値 | 2017071901 | |||||
| 閲覧数(XooNIps) | ||||||
| 値 | 468 | |||||
| ダウンロード数(XooNIps) | ||||||
| 値 | 353 | |||||
